{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T22:59:07Z","timestamp":1789167547337,"version":"build-2803163510"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:p>\n                    PSMA-targeted radioligand therapies with\n                    <jats:sup>177<\/jats:sup>\n                    Lu-PSMA-617 have shown promising response rates with favorable toxicity in patients with metastasized castration-resistant prostate cancer. We report a case of a 72-year-old man with metastatic castration-resistant prostate cancer having comorbidities of DM, HTN, and end-stage renal disease (ESRD) on regular hemodialysis. The patient received 2 doses of 7.4GBq of\n                    <jats:sup>177<\/jats:sup>\n                    Lu-PSMA-617, 6 weeks apart. There was complete resolution of prior\n                    <jats:sup>68<\/jats:sup>\n                    Ga-PSMA avid lesions, a significant decrease in serum PSA level, and symptomatic response after therapy. We suggest that patients with ESRD on dialysis can be safely treated with\n                    <jats:sup>177<\/jats:sup>\n                    Lu-PSMA radionuclide therapy.\n                  <\/jats:p>","DOI":"10.1097\/rlu.0000000000006112","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T20:01:44Z","timestamp":1757534504000},"page":"e276-e277","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Super Responder of 177Lu-PSMA-617 PSMA Therapy in Patient With End-Stage Renal Disease on Hemodialysis"],"prefix":"10.1097","volume":"51","author":[{"given":"Khulood","family":"Al Riyami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asiya","family":"Al Busaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Al Balushi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashid","family":"Rasheed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharjeel","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"key":"R1-20260305","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer [published online ahead of print, 2021 Jun 23]","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"R2-20260305","doi-asserted-by":"crossref","first-page":"12477","DOI":"10.18632\/oncotarget.7245","article-title":"Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer","volume":"7","author":"Ahmadzadehfar","year":"2016","journal-title":"Oncotarget"},{"key":"R3-20260305","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2214\/AJR.18.20845","article-title":"Radioligand therapy with 177Lu-PSMA for metastatic castration-resistant prostate cancer: a systematic review and meta-analysis","volume":"213","author":"Yadav","year":"2019","journal-title":"AJR Am J Roentgenol"},{"key":"R4-20260305","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1093\/ckj\/sfz101","article-title":"Renal outcomes of radioligand therapy: experience of 177lutetium-prostate-specific membrane antigen ligand therapy in metastatic castrate-resistant prostate cancer","volume":"13","author":"Gallyamov","year":"2019","journal-title":"Clin Kidney J"},{"key":"R5-20260305","doi-asserted-by":"crossref","first-page":"e213","DOI":"10.1097\/RLU.0000000000003912","article-title":"Excellent response to adapted low-dose 177Lu-PSMA-617 PSMA therapy in renal compromise patient","volume":"47","author":"Usmani","year":"2022","journal-title":"Clin Nucl Med"},{"key":"R6-20260305","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.3390\/cancers13123095","article-title":"Renal safety of [177Lu]Lu-PSMA-617 radioligand therapy in patients with compromised baseline kidney function","volume":"13","author":"Rosar","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R7-20260305","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.2967\/jnumed.118.223149","article-title":"177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients with a single functioning kidney","volume":"60","author":"Zhang","year":"2019","journal-title":"J Nucl Med"},{"key":"R8-20260305","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.2967\/jnumed.123.265577","article-title":"[177Lu]Lu-PSMA-617 therapy in a patient with chronic kidney disease","volume":"64","author":"Mercolli","year":"2023","journal-title":"J Nucl Med"},{"key":"R9-20260305","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.3390\/biomedicines10071575","article-title":"Baseline imaging derived predictive factors of response following [177Lu]Lu-PSMA-617 therapy in salvage metastatic castration-resistant prostate cancer: a lesion- and patient-based analysis","volume":"10","author":"van der Sar","year":"2022","journal-title":"Biomedicines"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006112","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T21:02:16Z","timestamp":1772744536000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,10]]},"references-count":9,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006112","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,10]]},"assertion":[{"value":"2025-04-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}